Trials / Completed
CompletedNCT04839380
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
An Open-Label, Single-Arm Study to Evaluate the Effect of Ruxolitinib 1.5% Cream on Itch in Adult Participants With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ruxolitinib cream | ruxolitinib cream 1.5% will be applied twice daily as a thin film |
Timeline
- Start date
- 2021-10-12
- Primary completion
- 2022-11-18
- Completion
- 2022-11-18
- First posted
- 2021-04-09
- Last updated
- 2023-10-31
- Results posted
- 2023-10-31
Locations
2 sites across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04839380. Inclusion in this directory is not an endorsement.